Sökning: L773:0284 186X OR L773:1651 226X >
Breast cancer hormo...
-
Fohlin, HelenaLinköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Regionalt cancercentrum
(författare)
Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up
- Artikel/kapitelEngelska2024
Förlag, utgivningsår, omfång ...
-
Medical Journal Sweden AB,2024
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-206400
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-206400URI
-
https://doi.org/10.2340/1651-226X.2024.40493DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Funding Agencies|King Gustaf the Vth Jubilee Clinic Cancer Foundations in Gothenburg; Swedish Cancer Society; Swedish Breast Cancer Association; Alice Swenzon Foundation; Walter Anderssons Foundation; Onkologiska Klinikerna i Linkoeping Forskningsfond
-
Background: Hormone receptor positivity predicts benefit from endocrine therapy but the knowledge about the long-term survival of patients with different tumor receptor levels is limited. In this study, we describe the 25 years outcome of tamoxifen (TAM) treated patients. Patients and methods: Between 1983 and 1992, a total of 4,610 postmenopausal patients with early-stage breast cancer were randomized to receive totally 2 or 5 years of TAM therapy. After 2 years, 4,124 were alive and free of breast cancer recurrence. Among these, 2,481 had demonstrated estrogen receptor positive (ER+) disease. From 1988, the Abbot enzyme immunoassay became available and provided quantitative receptor levels for 1,210 patients, for which our analyses were done. Results: After 5 years of follow-up, when all TAM treatment was finished, until 15 years of follow-up, breast cancer mortality for patients with ER+ disease was significantly reduced in the 5-year group as compared with the 2-year group (hazard ratios [HR] 0.67, 95% confidence intervals [CI] 0.55-0.83, p < 0.001). After 15 years, the difference between the groups remained but did not increase further. A substantial benefit from prolonged TAM therapy was only observed for the subgroup of patients with ER levels below the median (HR = 0.62, 95% CI 0.46-0.84, p = 0.002). Similarly, patients with progesterone receptor negative (PR-) disease did benefit from prolonged TAM treatment. For patients with progesterone receptor positive (PR+) disease, there was no statistically significant benefit from more than 2 years of TAM. Interpretation: As compared with 2 years of adjuvant TAM, 5 years significantly prolonged breast cancer-specific survival. The benefit from prolonged TAM therapy was statistically significant for patients with ER levels below median or PR-negative disease. There was no evident benefit from prolonged TAM for patients with high ER levels or with PR+ tumors.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Nordenskjold, AnnaSahlgrens Univ Hosp, Sweden
(författare)
-
Rosell, JohanLinköpings universitet,Institutionen för biomedicinska och kliniska vetenskaper,Medicinska fakulteten,Region Östergötland, Regionalt cancercentrum(Swepub:liu)johro19
(författare)
-
Ferno, MartenLund Univ, Sweden
(författare)
-
Fornander, TommyKarolinska Inst, Sweden
(författare)
-
Ryden, LisaLund Univ, Sweden
(författare)
-
Skoog, LambertKarolinska Inst, Sweden
(författare)
-
Nordenskjöld, BoLinköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US(Swepub:liu)bono64
(författare)
-
Stål, OlleLinköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US(Swepub:liu)ollst87
(författare)
-
Linköpings universitetAvdelningen för kirurgi, ortopedi och onkologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Acta Oncologica: Medical Journal Sweden AB63, s. 535-5410284-186X1651-226X
Internetlänk
Hitta via bibliotek
Till lärosätets databas